NCT05187832招募中1 期
A Phase I Dose Escalation and Dose Expansion Study of AND019 in Patients With Estrogen Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative Advanced or Metastatic Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 61
- 试验地点
- 1
- 主要终点
- PK study of AND019
研究概览
简要总结
This is a first in human dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of AND019 in postmenopausal women with advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor receptor 2 [HER2]-negative) breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Postmenopausal women defined as NCCN guideline at the time of informed consent.
- •Histological or cytological confirmation of advanced or metastatic ER+/HER2- breast cancer women who failed standard therapy or for which no standard therapy exists.
- •Prior therapy:
- •No more than 1 line of chemotherapy for advanced breast cancer
- •Recurrence or progression on at least one line of endocrine therapy in the advanced or metastatic disease setting and derived a clinical benefit from the endocrine therapy: Recurred or progressed while being treated with adjuvant endocrine therapy for a duration of at least 24 months, or progressed under endocrine therapy for more than 6 months in the advanced or metastatic setting
- •ECOG score 0-
- •Minimum life expectancy of a least 3 months as determined by the Investigator.
- •Evaluable disease per RECIST 1.1; for patients consent to tissue biopsy, disease suitable for tumor biopsy.
- •Sufficient bone marrow reserve and organ function.
排除标准
- •Previous treatment with any SERDs.
- •Patient any central nervous system metastasis.
- •Prior antitumor therapies:
- •Received chemotherapies within 3 weeks before the first dose.
- •Received systemic radiotherapy within 3 weeks before the first dose, or local radiotherapy within 7 days before the first dose
- •Received other anti-tumor therapy such as endocrine therapy, immunotherapy, and target therapy within 3 weeks or 5 half-lives of the drug before the first dose of the study drug
- •For bone metastasis, bisphosphonates and local remission therapy are allowed (7 days washout for local radiation therapy).
- •Patient who has participated in any other clinical trials for drugs or treatments within 5 half-lives for a prior investigational drug or 2 weeks from use of an investigational device prior to the first dose of study drug.
- •Patient who had major surgery or significant trauma within 4 weeks prior to the first dose of study drug (excluding needle biopsy), or has scheduled surgery during the study period.
- •Patient with serous unhealable wounds/ulcers/fractures within 4 weeks prior to the first dose of study drug.
- •Patient with adverse reactions to previous anti-tumor treatments who have not yet recovered to grade ≤1 according to CTCAE v5.
- •(except for toxicities without safety risks as judged by Investigator, such as alopecia, grade 2 peripheral neuropathy etc.)
- •Patient who has used strong inhibitors or strong inducers of CYP3A, or grapefruit or grapefruit juice within 4 weeks prior to the first dose of study drug.
- •Patient unable to be administered oral medications or any condition that seriously affect digestion in the gastrointestinal tract at the judgement of the Investigator.
- •Patient with active infection within 1 week prior to the first dose of study drug, and currently need systemic anti-infective treatment.
- •Patient has a known history of the following: HIV infection without effective antiretroviral therapy (ART) or acceptable immune function, or syphilis infection, or HBsAg positive HBV or needs prophylaxis therapy or suppressive antiviral therapy before dosing, or has an HCV infection that hasn't completed curative antiviral treatment or with unacceptable viral load.
- •Patient has active cardiac disease or a history cardiac dysfunction.
- •Patient with third spacing that cannot be controlled clinically and is not suitable for the study by the Investigator's judgment.
- •Patient with known history of drug abuse.
- •Patient with mental disorder that, in the opinion of the Investigator, could lead to poor compliance with required study procedures.
- •Patient that cannot tolerate venous blood sampling.
- •Known to have other malignancy within the past 5 years, and is progressing or requires active treatment (except skin basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma in situ who have received potentially radical treatment)
研究组 & 干预措施
AND019 single dose escalation and expansion
Experimental
Subjects will be administrated with AND019 capsule PO QD from 20 mg to 400 mg during Part 1, and 2 dose groups will be selected for dose expansion study
干预措施: AND019 PO QD (Drug)
结局指标
主要结局
PK study of AND019
时间窗: At predefined timepoints at Day 1, Day 8, Day 15, and Day 22 of Cycle 1, and Day 1 of each cycle starting from Cycle 2 (each cycle is 28 days)
Plasma concentration of AND019 over time
Number of participants with adverse events by severity, according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0
时间窗: From baseline to 12 weeks after the last dose of study treatment (up to 25 months)
Number of participants with adverse events
次要结局
- Percentage of Participants with Objective Response(Baseline and every 8 weeks from Cycle 1 Day 1 until Week 24, and then every 12 weeks until end of study treatment (up to 24 months) (each cycle is 28 days))
- Duration of Response(From the first occurrence of a documented objective response until first observation of disease progression or death from any cause on study, whichever occurs first (up to 24 months))
- Determine the RP2D(From baseline to up to the end of Cycle 1 (each cycle is 28 days))
- Clinical Benefit Rate(Baseline and every 8 weeks from Cycle 1 Day 1 until Week 24 (each cycle is 28 days))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or LymphomasSquamous Cell Carcinoma of the Head and NeckNon Small Cell Lung CancerUrothelial CarcinomaGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaSquamous Cell Carcinoma of the AnusSquamous Cell Carcinoma of the CervixSquamous Cell Carcinoma of the SkinDiffuse Large B Cell LymphomaMismatch Repair Deficient or MSI-High Solid TumorsMelanomaRenal Cell CarcinomaHodgkin LymphomaNCT03894618Shattuck Labs, Inc.49
已完成
1 期
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid TumorsAdvanced Solid Tumor CancersMedulloblastomaBasal Cell CarcinomaNCT00880308Novartis Pharmaceuticals103
已完成
1 期
A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid TumorsAdvanced Solid TumorsRecurrent or Refractory MedulloblastomaLocally Advanced or Metastatic Basal Cell CarcinomaNCT01106508Novartis Pharmaceuticals57
招募中
1 期
A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)AML, AdultNCT05947344Zhejiang ACEA Pharmaceutical Co. Ltd.84
已完成
1 期
Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid TumorsAdvanced CancerMetastatic CancerNeoplasmsNeoplasm MetastasisNeoplastic ProcessesPathologic ProcessesNCT03510104Meryx, Inc.42